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Introduction: Most patients with atrial fibrillation (AF) should receive anticoagulant therapy to reduce 
the risk of systemic embolization. However, there are varying degrees of bleeding risk associated with 
anticoagulation thus reducing the number of candidates for this therapy. The left atrial appendage 
(LAA) is the usual source of clot embolisms. Percutaneous approaches, often referred to as LAA exclu-
sion procedures, mechanically prevent embolization of LAA thrombi.1,2 We consider the placement of 
percutaneous LAA Occlusion Device (Amplatzer Amulet device) a good choice for patients with high 
bleeding risk.
Case report: We present a male, 67-year-old patient with permanent AF, diabetes mellitus, hyperten-
sion, (CHADS VASc Score 3) who was admitted to Department of Neurology with nontraumatic intrac-
erebral hemorrhage twice in the same year. First time during oral anticoagulation therapy with warfa-
rin and second time while receiving dabigatran. Since patient had recurrent bleeding on anticoagulant 
therapy, and his neurological deficit was fully recovered we considered him as ideal patient for LAA 
Occlusion Device implantation. A transesophageal echocardiogram (TEE) showed a large thrombus 
almost protruding from the  LAA to the left atrium (Figure 1), and treatment with low molecular weight 
heparin with consecutive monitoring with TEE every six weeks followed mild resolution of thrombus 
and the patient was sent to interventional cardiologist in University Hospital Centre Split where he 
was amicably admitted for the life threatening malignant thrombus. After the usual pre-procedural 
processing including MSCT left atrial angiography, patient was subjected for Amplatzer Amulet Oc-
cluding Device 31 mm, with no signs of early complications. Post-procedural patient was receiving 
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Figure 1.  Large thrombus protruding from the left atrial appenda-
ge to the left atrium.
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Figure 2. Amplazer Amulet Occluding Device; transesophageal 
echocardiogram – two chamber (atrial appendage) view.
dual antiplatelet therapy for six months. Six weeks after implantation TEE exam showed no thrombosis on device, no leak and clots 
inside the left atrium (Figure 2).
Conclusion: The importance of the LAA in thromboembolic risk among patients with AF provides the rationale for ligation, amputa-
tion, or occlusion of the LAA, especially in patients who are candidates for, but cannot receive oral anticoagulation, or those at high risk 
for bleeding with oral anticoagulation. 
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